This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Voduc, D. Articles by Nielsen, T. Search for Related Content PubMed PubMed Citation Articles by Voduc, D. Articles by Nielsen, T.

GATA-3 Expression in Breast Cancer Has a Strong Association with Estrogen Receptor but Lacks Independent Prognostic Value

¹ Genetic Pathology Evaluation Centre, University of British Columbia; ² Department of Radiation Oncology, BC Cancer Agency; and ³ Department of Pathology, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada

Requests for reprints: David Voduc, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6. Phone: 604-707-0595. E-mail: dvoduc{at}bccancer.bc.ca

Background: GATA-3 is a transcription factor involved in human growth and differentiation. Gene expression profiling has shown that GATA-3 is highly expressed in the Luminal A subtype of breast cancer. A recent study found GATA-3 to be associated with favorable breast cancer pathologic features, including negative lymph node and positive estrogen receptor (ER) status. GATA-3 levels were also found to be an independent prognostic marker, with low expression predicting for breast cancer recurrence.

Materials and Methods: Our case series consists of 3,119 cases of invasive breast cancer in which GATA-3 expression was assessed by immunohistochemistry on tissue microarrays. We considered >5% nuclear staining to be a positive result for GATA-3.

Results: Thirty-two percent of cases were GATA-3 positive. GATA-3 is almost exclusively expressed in ER+ patients and is also associated with lower tumor grade, older age at diagnosis, and the absence of Her2 overexpression. In univariate analysis, the presence of GATA-3 is a marker of good prognosis and predicted for superior breast cancer–specific survival, relapse-free survival, and overall survival. However, in multivariate models including patient age, tumor size, histologic grade, nodal status, ER status, and Her2 status, GATA-3 was not independently prognostic for these same outcomes. In the subgroups of ER+ patients treated with or without tamoxifen, GATA-3 was again nonprognostic for all outcomes.

Discussion: GATA-3 is a molecular marker that is highly associated with ER expression, but it does not seem to have prognostic value independent of ER, nor does it predict for response to tamoxifen among ER-positive patients. (Cancer Epidemiol Biomarkers Prev 2008;17(2):365–73)

This article has been cited by other articles:

				M. C. U. Cheang, S. K. Chia, D. Voduc, D. Gao, S. Leung, J. Snider, M. Watson, S. Davies, P. S. Bernard, J. S. Parker, et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer J Natl Cancer Inst, May 20, 2009; 101(10): 736 - 750. [Abstract] [Full Text] [PDF]

				M.-L. Asselin-Labat, F. Vaillant, M. Shackleton, T. Bouras, G.J. Lindeman, and J.E. Visvader Delineating the Epithelial Hierarchy in the Mouse Mammary Gland Cold Spring Harb Symp Quant Biol, November 19, 2008; (2008) sqb.2008.73.020v2. [Abstract] [PDF]